In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

AstraZeneca, UPenn partner for tau-mediated Alzheimer's; deal later ends

Executive Summary

AstraZeneca PLC and the University of Pennsylvania School of Medicine have agreed to work together on the development of new therapeutics for Alzheimer's disease. The collaboration comes after a successful three-year alliance signed in 2006 under which the entities researched various CNS conditions including addiction, cognition, anxiety, depression, and stress-related disorders.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Concluded
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies